Article
A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons - 1 Jul 2016
Shuker N, Bouamar R, van Schaik R H N, Clahsen-van Groningen M C, Damman J, Baan C C, van de Wetering J, Rowshani A T, Weimar W, van Gelder T, Hesselink D A
Abstract excerpt
Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose to achieve therapeutic exposure compared with nonexpressers. This randomized-controlled study investigated whether adaptation of the tacrolimus starting dose according to CYP3A5 genotype increases the proportion of kidney transplant recipients being within the target tacrolimus predose concentration range (10-15 ng/mL) at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.